Inhaled corticosteroid dose comparison

The recruited patients had a median (inter-quartile ranges) FENO level of 19 ppb (12-30 ppb). Patients with chronic cough had a significantly higher median FENO level than those with subacute cough ( vs 16 ppb; Z=-, P=). A FENO level ≥25 ppb was recorded in 15 (%) patients with subacute cough, as compared with 20 (%) in patients with chronic cough (χ(2)=, P=). With a FENO ≥25 ppb as the critical value to justify ICS treatment, 15 patients with subacute cough received ICS and 14 (%) of them showed obvious relief of cough after 2 weeks of therapy, a response rate similar to that of % (17/20) in patients with chronic cough receiving the treatment (χ(2)=, P=). In patients with subacute cough, those with cough variant asthma (CVA) or eosinophilic bronchitis (EB) had a significantly higher median FENO level than those with postinfectious cough [(16 (11-31) ppb vs 11 (8-19) ppb, P<]. In the etiological analysis, CVA or EB was identified in 23 (%) of the patients with subacute cough, as compared 21 (%) in patients with chronic cough (χ(2)=, P=).

Inhaled corticosteroid dose comparison

inhaled corticosteroid dose comparison

Media:

inhaled corticosteroid dose comparisoninhaled corticosteroid dose comparisoninhaled corticosteroid dose comparisoninhaled corticosteroid dose comparisoninhaled corticosteroid dose comparison

http://buy-steroids.org